Vaxxas announced that it received a $3.67 million award to conduct studies of a typhoid vaccine delivered by its needle-free device. The company develops a vaccine patch based on its proprietary HD-MAP delivery technology. Vaxxas designed its HD-MAP technology to use an ultra-high-density array of micro projections, invisible to the human eye. Applied to the […]
Vaxxas
Study backs self-administration with Vaxxas vaccine patch
Vaxxas today announced clinical trial data demonstrating the potential of its high-density microarray patch (HD-MAP) for vaccine delivery. The company published the data highlighting effective vaccine payload delivery in Human Vaccines & Immunotherapeutics. This counts for both trained professionals and individual self-administration. Vaxxas reported an equivalency of observed human skin response and vaccine delivery potential between […]
Vaxxas raises $23M for needle-free drug delivery tech
Vaxxas announced today that it completed a financing round that brings in $23 million (A$34 million) in new funds. Existing investors OneVentures and UniQuest led the round. New investors, including members of the company’s board and management team, along with individual investors, participated. The company earmarked proceeds to advance its clinical programs, including its needle-free […]
Vaxxas receives more than $5 million grant for vaccine delivery patch
Vaxxas announced today the Australian government is granting it nearly $5.5 million for the manufacturing of its vaccine delivery device. Cambridge, Massachusetts-based Vaxxas picked up AU$8.2 million ($5.48 million). The second-round grant represents part of the Australian government’s Modern Manufacturing Initiative (MMI). Funding supports the manufacturing scale-up of Vaxxas’ device for applying vaccines to the […]
Vaxxas licenses COVID-19 vaccine for patch delivery system, expects to finish Phase 1 trial this year
Vaxxas announced today that it was granted an exclusive license for a next-generation COVID-19 vaccine to be used with its delivery patch. Cambridge, Massachusetts-based Vaxxas received the license from The University of Texas at Austin for its HexaPro SARS-CoV-2 spike subunit vaccine. Get the full story at our sister site, Drug Delivery Business News.
HHS gives Vaxxas $22M to support vaccine patch tech
Vaxxas announced today that it has received a $22 million award from the Biomedical Advanced Research and Development Authority (BARDA) at U.S. HHS to support a clinical study involving the company’s vaccine-delivery patch. The money will mostly pay for a Phase 1 clinical study in which Vaxxas’ high-density micro-array patch (HD-MAP) delivering pandemic influenza vaccine to […]
Merck eyes tiny patches as a vaccine delivery method
Merck has exercised its option to use Vaxxas‘ High Density Microarray Patch (HD-MAP) platform as a delivery platform for a vaccine candidate, the companies announced today. The companies did not disclose what the vaccine candidate is supposed to treat. But Merck this month announced two COVID-19 vaccine development efforts: a collaboration with IAVI and plans […]